Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s

February 2016

More warnings for the SGLT2 inhibitors (Invokana, etc) will increase concerns about their safety.

These "flozins" are sometimes preferred because they have a low risk of hypoglycemia...lead to modest weight loss...and can lower BP.

Plus Jardiance (empagliflozin) has CV benefits including a reduced risk of cardiovascular death and heart failure hospitalizations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote